A5047152075- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Pneumonia and Respiratory Infections
- Pediatric health and respiratory diseases
- Respiratory viral infections research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Nosocomial Infections in ICU
- Respiratory and Cough-Related Research
- Dysphagia Assessment and Management
- Pneumocystis jirovecii pneumonia detection and treatment
- Respiratory Support and Mechanisms
- Mycobacterium research and diagnosis
- Asthma and respiratory diseases
- Emergency and Acute Care Studies
- Childhood Cancer Survivors' Quality of Life
- Tuberculosis Research and Epidemiology
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Diagnosis and Treatment
- Sepsis Diagnosis and Treatment
- Antibiotic Resistance in Bacteria
- Ultrasound in Clinical Applications
- Immunodeficiency and Autoimmune Disorders
- Congenital Diaphragmatic Hernia Studies
Vall d'Hebron Hospital Universitari
2017-2025
Vall d'Hebron Institut de Recerca
2017-2025
Hospital Clínic de Barcelona
2012-2024
Universitat de Barcelona
2014-2024
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2015-2024
Instituto de Salud Carlos III
2011-2024
Centro de Investigación Biomédica en Red
2017-2024
Universitat Autònoma de Barcelona
2020-2024
IRCCS Humanitas Research Hospital
2024
University of Manchester
2023
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management adult bronchiectasis describe appropriate investigation treatment strategies determined by systematic review literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology...
IMPORTANCEIn patients with severe community-acquired pneumonia, treatment failure is associated excessive inflammatory response and worse outcomes.Corticosteroids may modulate cytokine release in these patients, but the benefit of this adjunctive therapy remains controversial.OBJECTIVE To assess effect corticosteroids communityacquired pneumonia high response.DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind, placebo-controlled trial conducted 3 Spanish teaching...
There is a need for clear definition of exacerbations used in clinical trials patients with bronchiectasis. An expert conference was convened to develop consensus an exacerbation use research.A systematic review definitions from January 2000 until December 2015 and involving adults bronchiectasis conducted. A Delphi process followed by round-table meeting experts organised reach definition. These came Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North...
<h3>Background</h3> The distribution of the microbial aetiology and mortality community-acquired pneumonia (CAP) was investigated in relation to clinical setting severity scores (pneumonia index (PSI) confusion, blood urea nitrogen, respiratory rate, pressure, age (CURB-65)). <h3>Methods</h3> 3523 patients with CAP were included (15% outpatients, 85% inpatients). (PSI, CURB-65) relative different aetiologies across analysed. <h3>Results</h3> established 1463 (42%), whom 257 died (7%)....
Testing for underlying etiology is a key part of bronchiectasis management, but it unclear whether the same extent testing required across spectrum disease severity.
Bronchiectasis is a disease of renewed interest in light an increase prevalence and increasing burden on international healthcare systems. There are no licensed therapies, large gaps knowledge terms epidemiology, pathophysiology therapy. The European Multicentre Audit Research Collaboration (EMBARC) Respiratory Society (ERS) Clinical Collaboration, funded by ERS to promote high-quality research bronchiectasis. objective this consensus statement was define priorities From 2014 2015, EMBARC...
Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few low-income middle-income countries. We therefore aimed describe characteristics, severity of disease, microbiology, treatment patients bronchiectasis in India.The Indian registry multicentre, prospective, observational cohort study. Adult (≥18 years) CT-confirmed were enrolled 31 centres across India. Patients due cystic fibrosis or traction...
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Audit Research Collaboration) registry a prospective, pan-European observational study patients with bronchiectasis. inclusion criterion primary clinical diagnosis bronchiectasis consisting of: 1) history consistent bronchiectasis; 2) computed tomography demonstrating Core exclusion criteria...
Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes patients with frequently exacerbating disease not well described.Objectives: To establish if there is a “frequent exacerbator phenotype” bronchiectasis impact exacerbations on long-term outcomes.Methods: We studied enrolled from 10 centers Europe Israel, up to 5 years follow-up. Patients were categorized by baseline exacerbation frequency (zero, one, two, or three more per...
Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it not known whether associated with worse clinical outcomes independent of the underlying severity disease. This study analysed data from 2596 included 10 different centres across Europe and Israel, a 5-year follow-up period. Prevalence P. its impact on exacerbations, hospitalisations, quality life mortality was assessed. The prevalence 15.0% (n=389). higher univariate analysis (hazard ratio (HR)...
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations previous year pre-defined bacteria sputum.In this phase III, double-blind, placebo-controlled trial, were randomised 2:1 to twice-daily DPI 32.5 mg placebo treatment regimens consisting on/off cycles 14 28 days 48 weeks. The primary end-points time first exacerbation frequency exacerbations.A total 416 14-day regimen...
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations previous year predefined sputum bacteria. Patients were randomised 2:1 to twice-daily DPI 32.5 mg placebo 14- 28-day on/off treatment cycles 48 weeks. Primary end-points time first exacerbation frequency exacerbations. Enrolling countries α level split (0.049 0.001 cycles, respectively) differed from RESPIRE 1. (14 days (n=176)...
Bronchiectasis is a heterogeneous, neglected disease with few multicentre studies exploring the causes, severity, microbiology, and treatment of across Europe. This aim this study was to describe clinical characteristics bronchiectasis compare between different European countries.
Rationale: Bronchiectasis is classically considered a neutrophilic disorder, but eosinophilic subtypes have recently been described. Objectives: To use multiple datasets available through the European Multicentre Audit and Research Collaboration to characterize bronchiectasis as clinical entity focusing on impact of eosinophils exacerbations. Methods: Patients were included from five countries examine relationships between blood eosinophil counts phenotypes after excluding coexisting asthma....
COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions disease used across studies.
Background International guidelines recommend airway clearance management as one of the important pillars bronchiectasis treatment. However, extent to which is used for people with in Europe unclear. The aim study was identify use patients across different countries and factors influencing use. Methods This a prospective observational using data from European Multicentre Bronchiectasis Audit Research Collaboration (EMBARC) Registry between January 2015 April 2022. Prespecified options were...
This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis. Adults who were culture positive pre-defined potential respiratory pathogens (including Pseudomonas aeruginosa Haemophilus influenzae) randomised to DPI 32.5 mg or placebo administered twice daily 28 days (with 56 follow-up). Bacterial density sputum (primary end-point), pulmonary...
To identify pathogens that require different treatments in community-acquired pneumonia (CAP), we propose an acronym, "PES" (Pseudomonas aeruginosa, Enterobacteriaceae extended-spectrum β-lactamase-positive, and methicillin-resistant Staphylococcus aureus).To compare the clinical characteristics outcomes between patients with CAP caused by PES versus other pathogens, to risk factors associated infection PES.We conducted observational prospective study evaluating only immunocompetent...
Background. The recent Infectious Disease Society of America/American Thoracic guidelines for the management community-acquired pneumonia (CAP) in adults defined a predictive rule to identify patients with severe CAP determine need intensive care unit (ICU) admission. We clinically validated this rule.